NCT04887792RecruitingPhase 1/2
Acetazolamide for Treatment Resistant Schizophrenia
A Randomized Controlled Trial of Acetazolamide for Patients With Treatment Resistant Schizophrenia
Source: ClinicalTrials.gov · Last updated 7 Jul 2026
Brief summary (registry, in English)
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 15 Dec 2020
- Start date
- 1 Feb 2022
- Primary completion date
- 30 Dec 2027
- Lead sponsor
- Vishwajit Nimgaonkar, MD PhD
- Diseases
- Schizophrenia
- NCT number
- NCT04887792
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 60
- From 1 Feb 2022 to the primary completion date, 30 Dec 2027
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or prior treatment with ACZ or history of hypersensitivity to ACZ.
Other illness
- History or current medical/neurological illnesses that may lead to unstable course, e.g., epilepsy.
- Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease/adrenal failure; chronic closed angle-closure glaucoma.
Other
- Substance abuse in the past month/dependence past 6 months with the exception of methadone prescribed for opiate withdrawal.
- Pregnancy.
- Intellectual disability as defined in DSM 5.
Who the study is looking for
- Written informed consent.
- Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose).
- PANSS total score \> 60 and Score \> 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions.
- Stable dose of antipsychotic drug (APD) for \> 1 month, continued throughout the study.
- Not participating in another randomized controlled clinical trial (RCT).
Age in the registry: 18 years to 55 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St. John's Medical College Hospital Coordinator of this site? Confirm its status | Bangalore | India | Recruiting |
| University of Pittsburgh Coordinator of this site? Confirm its status | Pittsburgh | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.